Caris Downgrades Noven Pharma (NOVN) to Neutral
NOVN Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 82
Caris & Co. downgrades Noven Pharmaceuticals (Nasdaq: NOVN) from Buy to Neutral.
The downgrade follows news yesterday that the company will be acquired by Hisamitsu for $16.50/share. The stock surged more than 22% on the news yesterday.
At least one other research firm has issued a downgrade on shares of Noven today. To stay up-to-date on all the analyst calls on the stock, click here or go to http://www.streetinsider.com/stock_lookup_news.php?q=novn&type=analyst.
Noven Pharmaceuticals, Inc. engages in the research, development, manufacture, licensing, marketing, and sale of prescription pharmaceutical products.
The downgrade follows news yesterday that the company will be acquired by Hisamitsu for $16.50/share. The stock surged more than 22% on the news yesterday.
At least one other research firm has issued a downgrade on shares of Noven today. To stay up-to-date on all the analyst calls on the stock, click here or go to http://www.streetinsider.com/stock_lookup_news.php?q=novn&type=analyst.
Noven Pharmaceuticals, Inc. engages in the research, development, manufacture, licensing, marketing, and sale of prescription pharmaceutical products.
You May Also Be Interested In
- UPDATE: UBS Downgrades Avon Products (AVP) to Sell; Still Cautious Even After Sell Off
- Children's Hospital Colorado Launches New Website on iAPPS Product Suite
- UBS Maintains a 'Buy' on JPMorgan (JPM); Patient Investors Will Be Rewarded
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
